Insulet Corporation $PODD Stock Purchased by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP lifted its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 167.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 29,236 shares of the medical instruments supplier's stock after acquiring an additional 18,293 shares during the period. Fulcrum Asset Management LLP's holdings in Insulet were worth $3,884,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in Insulet by 7.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,872 shares of the medical instruments supplier's stock valued at $506,000 after purchasing an additional 263 shares during the last quarter. University of Texas Texas AM Investment Management Co. lifted its holdings in Insulet by 159.3% in the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 630 shares of the medical instruments supplier's stock worth $82,000 after buying an additional 387 shares during the period. Brighton Jones LLC grew its position in shares of Insulet by 85.0% in the 3rd quarter. Brighton Jones LLC now owns 9,341 shares of the medical instruments supplier's stock worth $1,219,000 after buying an additional 4,292 shares during the last quarter. Ethic Inc. grew its position in shares of Insulet by 2.5% in the 3rd quarter. Ethic Inc. now owns 11,369 shares of the medical instruments supplier's stock worth $1,483,000 after buying an additional 275 shares during the last quarter. Finally, Formidable Asset Management LLC bought a new stake in shares of Insulet in the 3rd quarter worth approximately $307,000.

Insulet Stock Up 2.3%

Shares of NASDAQ:PODD opened at $149.81 on Tuesday. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The firm has a market capitalization of $10.39 billion, a P/E ratio of 24.40, a P/E/G ratio of 1.25 and a beta of 1.06. The stock has a 50 day moving average price of $142.06 and a 200-day moving average price of $175.98. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating analysts' consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company had revenue of $842.00 million during the quarter, compared to analysts' expectations of $832.63 million. During the same quarter last year, the business posted $1.24 EPS. The firm's revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Insulet Corporation will post 6.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. UBS Group raised their price target on Insulet from $150.00 to $171.00 and gave the stock a "neutral" rating in a research note on Thursday, November 5th. Jefferies Financial Group reissued a "buy" rating and set a $200.00 price objective on shares of Insulet in a research report on Wednesday, November 4th. Weiss Ratings restated a "sell (d+)" rating on shares of Insulet in a report on Monday, September 21st. JPMorgan Chase & Co. upped their price objective on shares of Insulet from $152.00 to $170.00 and gave the stock a "neutral" rating in a report on Thursday, November 5th. Finally, Citigroup raised their target price on shares of Insulet from $150.00 to $170.00 and gave the stock a "neutral" rating in a research report on Thursday, November 5th. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $185.67.

Insulet Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.